Previous 10 | Next 10 |
Alkermes (ALKS): Q1 Non-GAAP EPS of $0.11 beats by $0.12; GAAP EPS of $0.14 beats by $0.49.Revenue of $251.4M (+2.1% Y/Y) beats by $16.17M.At Mar. 31, 2021, Alkermes recorded cash, cash equivalents and total investments of $627.4M, compared to $659.8M at Dec. 31, 2020. Total debt outstanding ...
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting - Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa - PR Newswire ...
Alkermes plc Reports First Quarter 2021 Financial Results -- First Quarter Revenues of $251.4 Million Reflect Solid Performance of VIVITROL® and ARISTADA® -- -- Achieves GAAP Loss per Share of $0.14 and Basic and Diluted Non-GAAP Earnings per Share of $0.11, Suppor...
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence Myrelationshipwithalcohol.com Provides Information About the Disease, Personal Stories and an Interactive Questionnaire to Assess Drinking Patterns PR Newswire DUBLIN , Apri...
Alkermes (NASDAQ:ALKS) is scheduled to announce Q1 earnings results on Wednesday, April 28th, before market open.The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $235.23M (-4.5% Y/Y).Over the last 2 years, ALKS has beaten EPS estimates 88% of the time and has be...
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma PR Newswire DUBLIN , April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the a...
Alkermes ([[ALKS]] +5.6%) rose sharply in the morning hours after Mizuho raised its price target by $1.00 to $29.00 per share to imply a ~36.3% upside to the previous close.The analyst Vamil Divan reiterates the buy rating and thinks the company is on track to beat consensus profit estimates....
Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results PR Newswire DUBLIN , April 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on ...
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society - New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia - PR Newswire DUBLIN , ...
Merck & Co. is a large legacy company that makes a profit, pays a consistent dividend, and is a familiar and dependable company. That sometimes makes for boring. Analysts have a consensus target price in the mid-$90s while it might be undervalued by over 50%. Merck develops an...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...